Zobrazeno 1 - 10
of 2 277
pro vyhledávání: '"ixekizumab"'
Autor:
Alessandro Falco, MD, Cristina Mugheddu, MD, Jasmine Anedda, MD, Laura Pizzatti, MD, Alice Tatti, MD, Brunella Conti, MD, Laura Atzori, MD
Publikováno v:
JAAD International, Vol 16, Iss , Pp 257-263 (2024)
Background: Erythrodermic psoriasis (EP) is a potentially life-threatening disease, and there is currently no consensus regarding its optimal treatment. Biological drugs approved for Psoriasis Vulgaris treatment have been used as alternatives to trad
Externí odkaz:
https://doaj.org/article/d048ac2da3434e41be35bc4557535e41
Autor:
Abhijeet Danve, Aisha Vadhariya, Jeffrey Lisse, Arjun Cholayil, Neha Bansal, Natalia Bello, Catherine Bakewell
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1333-1345 (2024)
Abstract Introduction Real-world data on ixekizumab utilization in axial spondyloarthritis (axSpA) are limited. We evaluated ixekizumab treatment patterns and health care resource utilization (HCRU) in patients with axSpA using United States Merative
Externí odkaz:
https://doaj.org/article/c4f2887dfd9a4844aaa9b63efe6ed612
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology, Vol Volume 17, Pp 1811-1814 (2024)
Biao Song,1– 3,* Xiaohan Liu,1– 3,* Hongzhong Jin1– 3 1Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People’s Republic of China; 2State
Externí odkaz:
https://doaj.org/article/45fbc7b721434aeea61ba3814e7a7609
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology, Vol Volume 17, Pp 1723-1728 (2024)
Yuan Li, Jiejie Lu, Jingqiu Fu Department of Cosmetic Dermatology, The Fifth People’s Hospital of Hainan Province, Haikou, Hainan, People’s Republic of ChinaCorrespondence: Jingqiu Fu, Department of Cosmetic Dermatology, The Fifth People’s Hosp
Externí odkaz:
https://doaj.org/article/d55baf79031341989c0cd6a1822c0f7a
Autor:
Xiaoxia Zhu, Jiankang Hu, Dongzhou Liu, Jingyang Li, Huaxiang Wu, Lingyun Sun, Lie Dai, Chunyu Tan, Zhijun Li, Zhengyu Xiao, Xiaomei Li, Yan Yan, Guanshen Dou, Yuzi Sun, Hejian Zou
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 4, Pp 1011-1022 (2024)
Abstract Introduction Ixekizumab, an interleukin 17A (IL-17A) inhibitor, has demonstrated rapid and sustained improvement in the signs and symptoms in patients with active radiographic axial spondyloarthritis (r-axSpA) in global and Chinese populatio
Externí odkaz:
https://doaj.org/article/8631d196342e472686f7d10b244e35b3
Autor:
Bucur S, Serban ED, Ileanu BV, Costache RS, Nicolescu AC, Constantin T, Costache DO, Constantin MM
Publikováno v:
Psoriasis: Targets and Therapy, Vol Volume 14, Pp 79-86 (2024)
Stefana Bucur,1,2 Elena-Daniela Serban,1 Bogdan Vasile Ileanu,3 Raluca Simona Costache,4,5 Alin Codrut Nicolescu,6 Traian Constantin,7,8 Daniel Octavian Costache,1,9 Maria-Magdalena Constantin1,2 1 2nd Department of Dermatology, “Carol Davila” Un
Externí odkaz:
https://doaj.org/article/15ed3da1699d4e038bd4453aa26fa752
Publikováno v:
Journal of Cutaneous Immunology and Allergy, Vol 7 (2024)
Externí odkaz:
https://doaj.org/article/9a81df5a6d3c4646adef5bb9647b75f7
Autor:
April W. Armstrong, Tarannum Jaleel, Joseph F. Merola, Alice B. Gottlieb, Saakshi Khattri, Cameron C. Helt, William N. Malatestinic, Sarah E. Ross, Marcus E. Ngantcha, Kurt de Vlam
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1615-1631 (2024)
Abstract Introduction Skin involvement in patients with psoriatic arthritis (PsA) worsens the severity and burden of disease. Ixekizumab (IXE), a selective interleukin (IL)-17A antagonist, was compared to placebo (PBO) in the SPIRIT-P1 (NCT01695239)
Externí odkaz:
https://doaj.org/article/3d639bca47a94f48a215a9ee1b30d788
Autor:
Mario Valenti, Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Diego Orsini, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1649-1657 (2024)
Abstract Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safet
Externí odkaz:
https://doaj.org/article/2457ce851f3b4d589b890cf51ca53d3c
Publikováno v:
Научно-практическая ревматология, Vol 62, Iss 2, Pp 154-161 (2024)
Modern pathogenetic therapy of inflammatory rheumatic diseases (IRD) is aimed not only at reducing disease activity (although achieving remission and low disease activity remains the main goal of treatment), but also at eliminating as quickly and com
Externí odkaz:
https://doaj.org/article/58f38eb088f24cf98166bc0ad1e7d2e0